Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14779158 | 0.86 | CA2 (0.50) | CA2CA1CA9 | |
| SCHEMBL16115817 | 0.84 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL16147887 | 0.82 | CA2 (0.33) | CA2CA1CA9 | |
| SCHEMBL18631400 | 0.82 | CA2 (0.37) | CA2CA1CA9 | |
| SCHEMBL16115208 | 0.80 | CA2 (0.33) | CA2CA1CA9 | |
| SCHEMBL16266356 | 0.80 | CA2 (0.40) | CA2CA1CA9 | |
| SCHEMBL16266354 | 0.80 | CA2 (0.40) | CA2CA1CA9 | |
| SCHEMBL17512324 | 0.80 | CA2 (0.33) | CA2CA1CA9 | |
| SCHEMBL575568 | 0.80 | CA2 (0.33) | CA2CA1CA9 | |
| SCHEMBL16137869 | 0.80 | CA2 (0.33) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102627712-B | Preparation method and application of Ziegler Natta catalyst for propylene polymerization | CHANGCHUN APPLIED CHEMISTRY | 2014-02-12 | — | — | CN | claimed |
| CN-102617763-B | Preparation method of ultrahigh molecular weight polyethylene | CHANGCHUN APPLIED CHEMISTRY | 2014-02-12 | — | — | CN | claimed |
| CN-102627708-B | Preparation method for high-activity Ziegler Natta catalyst and application thereof | CHANGCHUN APPLIED CHEMISTRY | 2014-02-12 | — | — | CN | claimed |
| CN-102627708-A | Preparation method for high-activity Ziegler Natta catalyst and application thereof | CHANGCHUN APPLIED CHEMISTRY | 2012-08-08 | — | — | CN | claimed |
| CN-102627712-A | Preparation method and application of Ziegler Natta catalyst for propylene polymerization | CHANGCHUN APPLIED CHEMISTRY | 2012-08-08 | — | — | CN | claimed |
| CN-102617763-A | Preparation method of ultrahigh molecular weight polyethylene | CHANGCHUN APPLIED CHEMISTRY | 2012-08-01 | — | — | CN | claimed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| CN-117941116-A | Ionic binders for solid state electrodes | 迪金大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| EP-3621141-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190229372-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10333172-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| CN-101432923-A | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEM CORP (JP) | 2009-05-13 | — | — | CN | disclosed |
| WO-2009035565-A1 | PROSTAGLANDIN ANALOGUES FOR IMPLANT DEVICES AND METHODS | QLT PLUG DELIVERY, INC (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20050004044-A1 | Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics | BOARD OF REGENTS | 2005-01-06 | — | — | US | disclosed |
| WO-2004091484-A2 | USE OF ORSAPONIN [3BETA, 16BETA, 17 ALPHA-TRIHYDROXYCHOLOST-5-EN22-ONE 16-0-(2-0-4-METHOXYBENZOYL-BETA-D-XYLOPYRANOSYL)-(1->3)-(2-0ACETYL-ALPHA-L-ARABINOPYRANOSIDE)] OR OSW-1 AND ITS DERIVATIVES FOR CANCER THERAPEUTICS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-10-28 | — | — | WO | disclosed |
| US-6753414-B2 | PREPARING NATURALLY OCCURRING SAPONINS SUCH AS OSW-L | UNIVERSITY OF IOWA RESEARCH FOUNDATION, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030069214-A1 | Process for preparing saponin compounds | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069214-A1 | Process for preparing saponin compounds | LSS, CYP51A1, CYP4F11 | CA2 3787/4885CA1 1515/4885CA9 645/4885 |
| US-20050004044-A1 | Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics | OSBP2, OSBP, OSBPL3 | CA2 4799/4885CA1 2210/4885CA9 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.